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ABSTRACT
Autism spectrum disorders represent a group of
developmental disorders with strong genetic underpin-
nings. Several cytogenetic abnormalities or de novo
mutations able to cause autism have recently been
uncovered. In this study, the literature was reviewed to
highlight genotype–phenotype correlations between cau-
sal gene mutations or cytogenetic abnormalities and
behavioural or morphological phenotypes. Based on this
information, a set of practical guidelines is proposed to
help clinical geneticists pursue targeted genetic testing
for patients with autism whose clinical phenotype is
suggestive of a specific genetic or genomic aetiology.
Autism spectrum disorders (ASDs) represent a
heterogeneous group of neurodevelopmental dis-
orders characterised by social and communication
deficits, accompanied by repetititive and stereo-
typed behaviours, with onset before 3 years of
age.
12From a diagnostic standpoint, ASDs coincide
with the Diagnostic and statistical manual of mental
disorders, 4th edition (DSM-IV) criteria for perva-
sive developmental disorders, including autistic
disorder, Asperger syndrome, childhood disintegra-
tive disorder, Rett syndrome and ‘‘pervasive devel-
opmental disorder not otherwise specified’’ (PDD-
NOS).
12However, the concept of ASD is some-
what complementary to DSM-IV categorical diag-
noses, because it underlines that autistic-like traits
and behaviours represent a continual spectrum
rather than clinically defined diagnostic categories.
3
The male:female sex ratio for autistic disorder is
4:1, implying an involvement of the X chromo-
some and/or imprinting mechanisms. Autism is
associated with seizures and mental retardation
(MR) in up to 30% and 80% of cases, respec-
tively.
45 A prenatal origin of the disease is
supported by neuroanatomical and neuroimaging
studies, showing abnormalities stemming from
disturbed neurodevelopmental processes physio-
logically occurring during the first and second
trimester of pregnancy.
67
Genetics strongly contributes to the pathogen-
esis underlying ASDs.
89Rett syndrome, a mono-
genic disorder affecting female carriers of
mutations in the MeCP2 gene,
10 has been described
in detail previously.
11 In this review, we focus on
the remaining ASDs and especially on autistic
disorder, the neuropsychiatric disorder with the
highest monozygotic twin concordance rate (73–
95%), the highest heritability (.90%, as estimated
by twin studies) and a noticeable sibling recurrence
risk (5–6% for non-syndromic autism).
89In addi-
tion the presence of mild autistic traits in first-
degree relatives of patients with autism points
towards a strong genetic component in ASD.
3
Linkage and association studies have identified
numerous susceptibility genes, located on various
chromosomes, especially 2q, 7q, 15q and the X
chromosome.
89The clinical heterogeneity of ASD
probably reflects the complexity of its genetic
underpinnings, involving multiple contributing
loci, genetic heterogeneity, epistasis and gene–
environment interactions.
9 Interestingly, epidemio-
logical studies reported an incidence of 2–5 in
10 000 newborn babies before 1985, whereas
studies performed after the year 2000 converge
upon rates of ASD as high as 20–60 in 10 000.
12 13
This increase may stem from the use of broader
diagnostic criteria and increased attention by the
medical community,
12 13 but a real increase in
incidence of ASD due to environmental and
epigenetic factors acting upon a genetically vulner-
able background is also likely.
9
Genetic screens represent a powerful tool when
dealing with monogenic mendelian disorders,
characterised by direct genotype–phenotype corre-
lations. In the case of complex disorders, such as
ASD, widespread genetic testing would not only be
expensive and time-consuming, but also generally
inappropriate due to the aetiological complexity
described above.
9 Nonetheless, there are at least
two instances where genetic testing can be
successfully used in complex disorder: to evaluate
the degree of genetic susceptibility to a certain
disease and to identify rare monogenic or cytoge-
netic forms of the disease. The appropriate use of
genetic testing in these two instances is good
clinical practice for the following reasons: (1) the
identification of susceptibility variants can allow
the implementation of prevention programmes, as
exemplified by familial breast and ovarian cancers
involving BRCA1 and BRCA2 mutations,
14 or
familial colon cancer;
15 (2) the identification of
the exact genetic cause of an otherwise un-
explained disease, especially when it affects chil-
dren, can significantly reduce the levels of guilt and
anxiety in parents and improve their compliance
with medical interventions and to rehabilitation
programmes.
During the past few years, genetic research in
ASDs has begun achieving some important suc-
cesses, including the identification of several
vulnerability loci and of a few cytogenetic
abnormalities or single-base mutations able to
cause autism (see below). In order to transfer this
recently acquired knowledge into clinical practice,
it is critical to define a set of phenotypic inclusion
criteria that must be met by affected probands to
justify their enrolment in a specific genetic testing
programme. Accordingly, these genetic screening
Reviewprogrammes must be designed to use clearly targeted, feasible
and cost-effective strategies. We reviewed the relevant literature
to look for specific correlations between ASD-causing gene
mutations or cytogenetic abnormalities and clinical ASD
phenotypes (mainly behavioural and/or morphological ASD
phenotypes). We hope this information will be useful to guide
clinical geneticists in establishing and implementing effective
genetic screening programmes for those patients with ASD
whose phenotype is suggestive of a specific genetic or genomic
aetiology.
SYNDROMIC AUTISM
Syndromic autism (ASD associated with a known cause)
represents approximately 10% of all ASD cases and is often
associated with malformations and/or dysmorphic features.
81 6
Unlike ‘‘idiopathic’’ or ‘‘primary’’ ASD, syndromic autism
shows an equal male:female sex ratio.
17 Syndromic autism can
be associated with well-known genetic or genomic disorders
(including fragile X syndrome, neurofibromatosis, tuberous
sclerosis, untreated phenylketonuria, and Angelman, Cornelia
de Lange and Down syndromes), with de novo chromosomal
rearrangements detectable by karyotyping (duplication of the
maternal 15q11-13 region, deletions of chromosome 2q37, 7q31,
22q11 and microdeletions of chromosome 22q11.2) and with
rare environmental events (prenatal central nervous system
infection by rubella or cytomegalovirus, prenatal exposure to
valproic acid or thalidomide).
81 6
The recent advent of array-based high-resolution genomic
analysis has dramatically increased the power to detect small de
novo genomic deletions and duplications, down to a few
kilobases in size, well below the threshold of detection by
standard chromosomal banding and karyotyping techniques. At
least four independent genome-wide studies have identified de
novo microdeletions, microduplications or copy number var-
iants (CNVs) associated with autism using array-comparative
genome hybridisation (CGH) techniques using either bacterial
artificial chromosome (BAC) or single-nucleotide polymorphism
arrays.
18–21 Jacquemont et al
18 found that 8 of 29 (27.5%) patients
with autism carrying microdeletions or microduplications of
1.4–16.0 Mb in size, including six de novo chromosomal
rearrangements presented with dysmorphic facial features.
Sebat et al
19 found de novo CNVs in 10% of trios with one
affected child (12 of 118) and in 1% of normal trios (2 of 196).
Although the clinical characteristics of de novo CNV carriers
were not described in detail, they were interestingly not found
to be at increased risk of MR and some were apparently
diagnosed with Asperger syndrome, suggesting that CNVs may
also be associated with milder forms of autism, perhaps not
accompanied by dysmorphic features. Marshall et al
20 assessed
427 unrelated patients with ASD and 500 controls, finding 27
(6.3%) cases carrying de novo CNVs, which may be especially
present in simplex (4/56=7.1%) rather than in multiplex (1/
49=2.0%) families. Many, but not all patients, display
dysmorphic features and/or neurological impairment.
Christian et al
21 reported the presence of 7 de novo and 44
inherited CNVs in 397 patients with ASD. The clinical features
were not discussed in detail, but no evidence of signs or
symptoms shared by patients carrying de novo chromosomal
microdeletions or microduplications was reported. Using array-
based technologies, others have reported novel and possibly
recurrent microdeletion syndromes, affecting regions such as
16p11.2 and 2p15–16.1.
22–24 These studies have confirmed that
CNVs can be associated with a variety of clinical features,
including non-ASD behavioural disorders in siblings of patients
with autism. Therefore, the presence of malformations,
dysmorphic features and/or severe neurological symptoms
strongly points toward a possible cytogenetic origin for ASDs,
but their absence does not exclude it. The progressive transfer of
array-based approaches from the laboratory into clinical practice
will enhance our ability to detect an increasing number of
submicroscopic de novo chromosomal abnormalities.
GENES INVOLVED IN MONOGENIC FORMS OF AUTISM
Neuroligin 3/4 genes (NLGN3, NLGN4)
Neuroligins are cell-adhesion molecules localised postsynatpti-
cally in both glutamatergic (NLGN1, NLGN3, NLGN4,
NLGN4Y) and gamma-aminobutyric acid-ergic (NLGN2)
synapses.
92 5They interact with presynaptic b-neurexin, trigger-
ing the formation of functional presynaptic structures in
contacting axons. They also associate with postsynaptic
scaffolding proteins, such as SHANK3, also involved in ASD
(see below). The NLGN3 and NLGN4 genes, located at human
chromosome loci Xq13 and Xq22.33, respectively, have been
found to host rare mutations explaining ,1% of ASD cases
(table 1). Jamain et al
26 reported a frameshift (D396X in NLGN4)
and a missense (R451C in NLGN3) mutation in two unrelated
Swedish families, both mutations inherited from unaffected
mothers. In vivo studies using D396X or R451C mouse mutants
showed increased inhibitory synaptic transmission and impaired
social interaction,
27 paralleled by functional studies showing
Table 1 Neuroligin 3/4 genes and autistic spectrum disorders
Reference Patients with ASD, n (sex)
Hemizygous
mutations, n (%) Mutations/deletions Clinical phenotype
Jamain et al
26 158 (140M,18F) 2/158 (1.26) NLGN4: D396X,* NLGN3: R451C* Autism or Asperger syndrome
Blasi et al
37 124 (all M) — — —
Vincent et al
34 196 (149M,47F) — — —
Laumonnier et al
31 1 family with 13 affected males 13{ NLGN4: D429X* Mental retardation, autism, PDD-NOS
Ylisaukko-oja et al
36 30 (26M, 4F) — — —
Yan et al
33 148 (122M, 26F) 3/148 (2) NLGN4: G99S,{ K378R,* 403M,* R704C* Mild to severe autism, PDD-NOS
Gauthier et al
35 96 (83M,13F) — — —
Wermter et al
38 107 (102M, 5F) — — —
Lawson-Yuen et al
32 1 family (1 affected male) 1 Del NLGN4, exons 4,5,61 Autism with motor tics
Total 861 7/861 (0.8) — —
ASD, autistic spectrum disorders; PDD-NOS, pervasive developmental disorder not otherwise specified.
*Mutations also found in heterozygous asymptomatic mothers and/or other unaffected family members.
{Counted as a single mutation, because these were consanguineous individuals from the same large pedigree.
{Mutation found to be heterozygous in a female patient and in her mother (affected by a learning disability).
1Mutation found to be heterozygous in the patient’s mother (learning disorder, anxiety and depression) and his brother (Tourette syndrome).
Reviewdefective vesicle-trafficking and synapse-induction properties.
28–
30 Extensive genetic screens conducted by several groups have
confirmed the low frequency of neuroligin mutations among
patients with ASD (7/861; 0.8%; table 1). Laumonnier et al
31
found a frameshift mutation (D429X in NLGN4) in 13 affected
male members of a single pedigree (counted as one instance in
table 1, because they are related individuals coming from a
single pedigree). Lawson-Yuen et al
32 identified a deletion of
exons 4–6 of NLGN4 in an boy with autism and in his brother
with Tourette syndrome; the mutation was inherited by the
mother who also had neuropsychiatric disorders. Yan et al
33
reported four other NLGN4 missense mutations in patients
with ASD (G99S, K378R, V403M and R704C). However,
V403M and R704C were also found in unaffected siblings,
suggesting they could represent rare non-synonymous variants
rather than true mutations. None of 553 patients with ASD
assessed in five other studies were found to carry NLG3 or
NLG4 non-synonymous variants.
34–38 In contrast, novel splice
variants were identified in autistic individuals by Talebizadeh
et al.
39
The clinical phenotype of human NLG mutation carriers is
very heterogeneous. In both pedigrees carrying the D396X and
R451C mutations, two affected brothers carrying the mutated
gene were diagnosed, one with Asperger syndrome (the ‘‘speech-
preserved’’ variant of autism) and the other with autistic
disorder. The extended pedigree carrying the D429X frameshift
mutation in NLGN4 encompasses 10 male carriers affected with
non-specific X-linked MR, two male carriers with autism and
one with PDD-NOS (the autism variant not satisfying all
diagnostic criteria). Individuals carrying microdeletions invol-
ving the NLGN4 may even satisfy diagnostic criteria for
neuropsychiatric disorders apparently unrelated to ASDs.
32 In
addition, the G99S and K378R mutations yield broad clinical
heterogeneity, ranging from language disability to severe
autism. Mutation carriers typically display no dysmorphic
features, but interestingly they can undergo regression at
disease onset, characterised by a loss of initially acquired social
and verbal milestones. NLG mutations thus clearly exemplify
how regression does not necessarily imply the existence of
environmental factors striking at the time when behavioural
abnormalities become apparent, but simply stems from damage
to neural networks becoming evident at the time when they
should come ‘‘on-line’’ in order to support the harmonious
growth and expansion of social cognition.
In summary, NLG mutation carriers display a variety of
syndromes, ranging from X-linked MR without autism, to
Asperger syndrome, autistic disorder of variable severity and
PDD-NOS. Disease onset may be insidious or abrupt and
regressive. These patients do not share any morphological or
dysmorphic feature apt to spur a specific diagnostic investiga-
tion. The low frequency of these mutations and the lack of
phenotypic traits suggesting the involvement of NLG3 and
NLG4 do not encourage the clinical implementation of wide-
spread genetic screens for these genes in patients with non-
syndromic ASD.
SH3 and multiple ankyrin repeat domains 3 gene (SHANK3)
The SHANK3 gene is located on the telomeric terminal of
chromosome 22q13.3 and encodes for a scaffolding protein
found in the postsynaptic density (PSD) complex of excitatory
synapses, where it binds directly to neuroligins. Two recent
studies have shown a possible correlation between mutations or
small cytogenetic rearrangements affecting SHANK3 and an
ASD phenotype mainly characterised by severe verbal and social
deficits (table 2).
40 41 Similar to neuroligin mutations, SHANK3
mutations, deletions or duplications are rare, occurring in only
1.1% of patients with ASD. However, the genotype–phenotype
correlation reported in both studies suggests that patients with
autism with severe language and social impairment might be
good candidates for SHANK3 mutation screening. Five of seven
cases reported to date carry deletions (142 kb to 4.36 Mb in
size), of the terminal 22q13 region encompassing SHANK3,
whereas the other two have a frameshift (E409X) and a
missense mutation (Q321R).
40 41 Furthermore, rare non-synon-
ymous variations present in the ASD group, but not in the
control sample, were also found in both studies.
40 41 However,
these variations were inherited from healthy parents and
sometimes were also present in unaffected siblings, suggesting
that they may confer vulnerability rather than play a dominant
role in ASD pathogenesis. Indeed two of the mutations (R12C
and R300C) were associated with severe language problems and
social interaction difficulties. In vitro overexpression of these
variants resulted in diminished colocalisation with the pre-
synaptic marker protein Bassoon, suggesting nonsynaptic
clustering of mutated SHANK3.
40 Incomplete penetrance of
these variants could explain their presence in other unaffected
family members. Alternatively, they may cause the disease by
acting synergistically with other susceptibility genes.
It is interesting that both studies reported an inherited 22q13
deletion involving SHANK3 (800 kb in Durand et al
40 and
3.2 Mb at 22q13 in Moessner et al
41), stemming from a paternal
balanced translocation. In both studies, the probands with
autism had siblings with partial 22q13 trisomy affected by
disorders as different as Asperger syndrome with early language
development
40 and attention deficit hyperactivity disorder.
41
These observations suggest that fine-tuning of SHANK3 gene
dosage may be crucial for the development of language and
social cognition in humans.
The neurexin 1 gene
Presynaptic neurexins induce postsynaptic differentiation in
contacting dendrites, by interacting with their postsynaptic
neuroligin partners.
92 5 The three neurexin genes (NRXN1,
NRXN2 and NRXN3, located at the human chromosome loci
2q32, 11q13 and 14q24.3-q31.1, respectively) have two inde-
pendent promoters, which determine two mRNA classes: long
mRNAs, encoding for a-neurexins and short mRNAs, encoding
for b-neurexins.
42 A mutational NRXN1b screening conducted
by Feng et al
43 on 264 patients with ASD identified two
heterozygous missense mutations (S14L and T40S) and a GG
insertion in position 26 of the corresponding protein (table 3).
The two missense mutations were present in 4/264 (1.5%)
patients with ASD and not in 729 controls, but they also
occurred in first-degree relatives (parents and/or unaffected
siblings), who displayed very heterogeneous phenotypes ranging
from hyperactivity, depression and/or learning problems to
apparently normal behaviour. Similarly, one of two chromoso-
mal rearrangements affecting the NRXN1 gene were also shown
to be paternally inherited in one patient.
44 The same study also
reported two rare missense variants (L18Q and L748I) in 2 of 57
people with ASD.
44 People with autism carrying the S14L
mutations apparently have seizures and facial dysmorphisms.
43
No clinical and family data were reported for patients carrying
the insertion. In another study, a de novo heterozygous 300 kb
deletion in the coding exons of the NRXN1 gene was found in
two affected sisters, who both received a diagnosis of autism.
45
However, one girl was reported to be non-verbal, whereas the
other had mild language regression.
45 In a recent case–control
Reviewstudy by Yan et al,
46 five rare patient-specific variants were
identified in 116 ASD individuals whereas only one additional
variant (G28A) was also found in controls. Unfortunately, no
clinical or family data are available for this study.
The presence of deletions or other mutations also in unaffected
siblings of patients with autism and even in controls,
43 44 46
suggest that such mutations could confer vulnerability to ASD
rather than causing the disease. In addition, the small number of
studies performed to date on the putative link between neurexin
genes and autism suggest caution in addressing potential
genotype–phenotype correlations.
The methyl-CpG-binding protein 2 gene
Methyl-CpG-binding protein 2 (MeCP2) is a transcriptional
repressor that binds to methylated CpG dinucleotides generally
located at gene promoters and recruits HDAC1 and other
proteins involved in chromatin repression.
11 De novo mutations
of the MECP2 gene located on chromosome Xq28 occur in 80%
of female patients with Rett syndrome, a pervasive develop-
mental disorder generally characterised by regression, autism,
microcephaly, stereotyped behaviours, epilepsy and breathing
problems, whereas in males, mutations are generally lethal.
10 11
Some mutations can also result in asymptomatic phenotypes,
mild MR and verbal Rett variants.
11 The clinical phenotype
depends upon the type of mutation and the specific
X-inactivation pattern, which is highly skewed in the presence
of mutations affecting X-linked genes, such as NLGN3 and
MECP2, but is not significantly skewed in ASD families
overall.
47
Several groups have screened the MECP2 gene for mutations
in patients with non-syndromic ASD (table 4).Of 11 studies, 2
have identified de novo MECP2 mutations in female patients
with ASD: a de novo splice variant in intron 2 (IVS2 +
2delTAAG), a frameshift mutation (1157del41) and a nonsense
mutation (R294X).
48 49 Interestingly, the phenotype associated
with this mutation includes MR but not epilepsy, microcephaly,
stereotypies or any of the symptoms characteristic of Rett
syndrome; regression was present in one patient, but not in the
other two.
48 49 Another study identified two de novo mutations
(R133C and R453X) in girls with ASD fulfilling the criteria for
the preserved speech variant of Rett syndrome.
50 The remaining
eight studies were either entirely negative or reported missense,
intronic or 39-untranslated region variants potentially of
functional interest; either these were reported to be inherited
from one of the parents or it was not specified whether they
were inherited or de novo.
51–58 Overall, MECP2 mutations are
rare in the autistic population, accounting for 0.8–1.3% of cases
in the female ASD population (ie, 3/378 or 5/397, respectively,
depending whether patients from the Zappella et al study
50 are
included (table 4) and not including subjects from the
Shibayama et al
53 study for which no male:female ratio is
provided). Importantly, female patients with ASD carrying
MECP2 mutations appear mentally retarded, but do not display
any clinical trait resembling Rett syndrome. Signs and
symptoms more typical of Rett syndrome may be of later
onset, requiring that female patients with ASD be clinically
monitored over time.
59
The homeobox A1 gene
HOXA1 is a homeobox gene located at human chromosome
locus 7p15.3, essential to the development of head and neck
structures, including hindbrain, ear, and occipital and hyoid
bones.
60 61 Homozygous recessive stop-codon mutations of this
gene have been found in nine people belonging to four
consanguineous families from Saudi Arabia and one from
Turkey.
62 63 Two different mutations were identified: a
84CRG mutation results in the introduction of a stop codon
in the Turkish person, and a 175–176insG causes a reading
frame shift and premature protein truncation in the Saudi
Arabian patients. The probands of these families showed a
similar phenotype characterised by horizontal gaze abnor-
malities, deafness, focal weakness, hypoventilation, vascular
Table 2 SHANK3 and autistic spectrum disorders
Reference
Patients
with ASD, n
De novo
mutations, n (%) Mutations/deletions Clinical phenotype
Durand et al
40 227 3/227 (1.3) 142 kb del at 22q13, E409X, 800 kb del at 22q13* Autism with severe language and social deficits
Moessner et al
41 400 4/400 (1) 277 kb del at 22q13, 3.2 Mb del at 22q13,* 4.36 Mb
del at 22q13, Q321R
Autism with non-verbal communication and social deficits
Total 627 7/627 (1.1) — —
ASD, autistic spectrum disorders.
*Parents have a balanced translocation.
Table 3 Neurexin 1 and autistic spectrum disorders
Reference
Patients with
ASD, n
De novo
mutations, n (%) Mutations/deletions Clinical phenotype
Feng et al
43 264 (219M+45F) 0/192 (0) S14L*, T40S,* 26insGG{ Autism with seizures and facial
dysmorphism
The Autism Genome
Project Consortium
45
196 2/196{ (0.5) 300 kb del at 2p16 Autism with mild to severe spoken
language deficits
Kim et al
44 57 0/57 (0) ins(16;2)(q22.1;p16.1p16.3).* t(1;2)(q31.3;p16.3).1
L18Q,{ L748I*
—
Yan et al
46 116 0/116 (0) R8P, L13F, G28A,* c1024 +1G RA,{ T665I,{ E715K{ —
Total 633 1/633 (0.15) — —
ASD, autistic spectrum disorders.
*Mutations found also in other non-affected family members or in controls.
{No clinical and pedigree information available; not specified if occurring de novo.
{Counted as ‘‘1’’, because affected members were consanguineous relatives from the same pedigree.
1Rearrangement localised ,750 kb 59 to the NRXN1 locus.
Reviewmalformations of the internal carotid arteries and cardiac
outflow tract, MR and autism in some, but not all patients:
this clinical set of symptoms and malformations was named
Bosley–Salih–Alorainy syndrome (BSAS).
63
The phosphatase and tensin homologue gene
PTEN is a tumour suppressor gene located on human chromo-
some 10q23, influencing G1 cell-cycle arrest and apoptosis. In
the central nervous system, PTEN inactivation results in
excessive dendritic and axonal growth with increased numbers
of synapses.
64 Germline mutations resulting in PTEN haploin-
sufficiency thus facilitate cell-cycle progression and oncogenesis,
leading to macrocephaly/macrosomy and to cancer develop-
ment, respectively.
65 Germline PTEN mutations have been
found in approximately 80% of individuals diagnosed with
Cowden syndrome, accompanied by enhanced risk for breast,
endometrial and thyroid malignancies.
65 People with other
related hamartoma disorders, such as Bannayan–Riley–
Ruvalcaba syndrome, Proteus and Proteus-like syndromes dis-
play germline PTEN mutations in 60%, 20% and 50% of cases,
respectively.
65 In addition, somatic PTEN mutations have been
found in a variety of human tumours.
65 Interestingly, genetic
syndromes due to PTEN germline haploinsufficiency, in addi-
tion to excessive, dysplastic or neoplastic growth, are often
characterised by autism or MR and progressive macrocephaly, as
initially reported by Goffin et al.
66 A study by Butler et al
67
identified three de novo heterozygous PTEN germline muta-
tions in 18 (16.6%) people with macrocephaly and autism
(table 5). The three newly identified mutations all lead to
missense changes in evolutionarily conserved aminoacid resi-
dues. Others found PTEN mutations in different percentages of
macrocephalic patients with ASD
68–70 (in one case also display-
ing polydactyly of both feet).
70
Cases of ASD with PTEN mutations are invariably char-
acterised by severe to extreme macrocephaly (ie, cranial
circumference .97th percentile or +2 SD, but PTEN mutation
carriers with ASD typically display >+3 SD). Macrocephaly has
been consistently found in approximately 20% of patients with
autism recruited in independent samples.
71–75 Head circumfer-
ence in these patients with ASD is typically normal at birth and
an overgrowth seemingly develops over the first few years of
life.
76 Interestingly, the majority of macrocephalic patients are
actually macrosomic, as head size is significantly correlated with
excessive height and weight in this subgroup of patients with
autism.
77 The incidence of PTEN de novo mutations in these
macrocephalic/macrosomic patients with ASD can be estimated
at 4.7% (6/126) (table 5). Importantly, these patients are at
increased risk of developing a variety of PTEN-related cancers
during adulthood.
GUIDELINES FOR GENETIC COUNSELLING
Based on the information summarised above, we have defined a
set of practical guidelines that clinical geneticists should
consider, together with recently reviewed ethical issues,
78 when
providing genetic counselling to parents of autistic children.
c I fac o u p l eh a san o n - s y n d r o m i ca u t i s t i cc h i l d ,t h e
probability that a second child will also be autistic is
approximately 5–6%.
c A karyotype and fragile-X testing must be requested for all
patients with ASD.
c Clinicians should be aware that prenatal genetic testing
typically raises unrealistic expectations in parents of
children with autism because, with the exception of rare
gross chromosomal rearrangements, the genetic or genomic
anomalies responsible for ASD are not detectable using
current prenatal screening methods.
c In the presence of dysmorphic features and evident
neurological symptoms, it is reasonable to suspect chromo-
somal rearrangements even if the karyotype appears normal.
Depending upon availability and cost, a BAC or oligo array-
based CGH analysis is strongly advised in these cases. As
these technologies will become progressively more available,
it will be important not to restrict them to patients
with dysmorphia, as microdeletions and microduplications
are also common among patients with idiopathic, non-
dysmorphic ASD.
c Patients with NLG3 and NLG4 mutations do not share any
specific clinical features and the frequency of these muta-
tions is sufficiently low that widespread screening for
neuroligin mutations do not seem to be clinically justified.
c For the same reasons and owing to the small number of
studies performed to date, widespread screening for the
neuroxin genes are also not advisable at present.
Table 4 MECP2 and autistic spectrum disorders
Reference
Patients with
ASD, n
De novo
mutations, n (%)
Mutations/
deletions Clinical phenotype
Lam et al
48 21 (all F) 1/21 (4.8) IVS2+2delTAAG Autism and MR. No regression, epilepsy or microcephaly
Vourc’h et al
51 59 (42M,17F) — — —
Beyer et al
52 202 (154M,48F) — — —
Carney et al
49 69 (all F) 2/69 (2.9) 1157del41, R294X Autism, MR and history of regression. No stereotypies,
epilepsy or microcephaly
Zappella et al
50 19 (all F) 2/19 (4.7) R133C, R453X Preserved speech variant of Rett syndrome
Shibayama et al
53 24{ 0/24 (0) c1638 GRC,* c 6809 TRC,* P376R{ —
Lobo-Menendez et al
54 99 (58M,41F) – – —
Li et al
55 65 (49M,16F) — — —
Xi et al
56 31 (all M) 0/31 (0) 1 39UTR variant* —
Harvey et al
57 401 (266M,135F) — — —
Coutinho et al
58 172 (141M,31F) 0/172 (0) 12 39UTR variants.{ 2 intronic variants,{
G206A*
—
Total 397F, 741M{ 5/397 females (1.3),
0/741 males
——
ASD, autistic spectrum disorders; MR, mental retardation; UTR, untranslated region.
*Mutations found also in other non-affected family members or in controls.
{Not specified if occurring de novo; no pedigree information available.
{The study by Shibayama et al
53 did not provide an M:F ratio and was excluded from the total.
Reviewc Genetic screening programmes for the SHANK3 gene can
potentially be implemented for patients with severe verbal
and social deficits, bearing in mind that some SHANK3
mutations have also been found to be transmitted to
unaffected siblings of ASD probands (see table 1 in
Moessner et al
41).
c MECP2 genetic testing should be performed in all girls with
ASD and MR, remembering that clinicians should not
expect these patients to bear any resemblance to Rett
syndrome (ie, girls with autism carrying MECP2 mutations
will have normal head size, a history of regression may be
present or absent, and they will usually show no stereo-
typies or seizures).
c HOXA1 mutations are recessive. It is thus reasonable to
screen only patients from consanguineous families, when
presenting with autism associated with deafness, troncoen-
cephalic anomalies and especially horizontal gaze abnorm-
alities.
c The PTEN gene should be screened for mutations in all
children with autism and extreme macrocephaly (>3 SD).
Because of the tumour susceptibility produced by PTEN
haploinsufficiency, it is strongly advised to start an
oncological monitoring programme immediately for patients
with ASD carrying PTEN mutations.
c If the parents of a macrosomic autistic child (carrying no
genomic rearrangement or mutation affecting the genes
discussed above) decide to have another child, clinicians
should monitor weight, height and head circumference of
the baby sibling at regular intervals from birth to 2 years of
age (ie, during the clinical ‘‘latency’’ phase that precedes the
onset of autistic symptoms). If the neonate displays a
progressive overgrowth of head and body size compared
with age-specific and sex-specific population norms, it is
advisable to start an early intervention programme, wher-
ever available, with the aim of stimulating social cognition
at 18–24 months of life.
The design of behavioural intervention programmes targeted
to address ASD signs and symptoms as early as possible (ie,
before the age of 3 years) is being actively pursued in many
clinical centres, in order to intervene during the critical period of
maximum plasticity in postnatal brain development.
79 Within
this context, working in conjunction with paediatricians and
child neuropsychiatrists, clinical geneticists can significantly
contribute not only to the diagnostic process, but also to
successful implementation of the most appropriate behavioural
intervention programme. By designing and implementing
clinically targeted genetic screens, as proposed in our guidelines,
clinical geneticists will provide medically relevant information
while decreasing the level of anxiety and guilt in the parents,
thereby increasing their compliance with the pharmacological
and behavioural treatment of their child with autism.
Transferring the latest knowledge from autism genetic research
into clinical practice may not yet provide all the definitive
answers that investigators and clinicians would have wished to
have reached at this time, but can certainly contribute to raise
the clinical management of these patients and their families
beyond current standards.
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